Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

K&S CLINICAL DIAGNOSTICS CONSULTING SERVICES, LLC

NPI: 1891135299 · ATLANTA, GA 30339 · Clinical Medical Laboratory · NPI assigned 06/28/2013

$229K
Total Medicaid Paid
46,251
Total Claims
40,094
Beneficiaries
39
Codes Billed
2018-01
First Month
2024-11
Last Month

Provider Details

Authorized OfficialAWAD, MAGED (CHIEF MED OFFICER)
NPI Enumeration Date06/28/2013

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 16,216 $43K
2019 13,559 $79K
2020 9,631 $62K
2021 3,505 $20K
2022 1,674 $11K
2023 1,151 $7K
2024 515 $7K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 18,517 16,255 $148K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 20,071 17,160 $58K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 264 227 $10K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,037 763 $9K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,156 1,083 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 529 409 $1K
87481 244 218 $761.76
87653 254 221 $761.76
80156 193 168 $122.94
80175 192 167 $109.26
80350 115 105 $69.12
80354 115 105 $69.12
80357 115 105 $61.02
80366 115 105 $61.02
80360 115 105 $61.02
80359 115 105 $60.03
80355 115 105 $50.85
82570 388 334 $15.92
81003 388 334 $6.88
80363 115 105 $0.00
80353 115 105 $0.00
80371 115 105 $0.00
80368 115 105 $0.00
80358 115 105 $0.00
80201 28 25 $0.00
80367 115 105 $0.00
80375 115 105 $0.00
80346 115 105 $0.00
80348 115 105 $0.00
80325 115 105 $0.00
83992 115 105 $0.00
80361 115 105 $0.00
80370 115 105 $0.00
80338 115 105 $0.00
80356 115 105 $0.00
80365 115 105 $0.00
80373 115 105 $0.00
80372 115 105 $0.00
80323 115 105 $0.00